BIOPHYTIS ORGANISES A WEBCAST WITH KEY OPINION LEADERS (KOL) ON THE PHASE 2-3 COVA STUDY RESULTS OF SARCONEOS (BIO101) IN THE TREATMENT OF PNEUMONIA IN COVID-19 PATIENTS AT RISK OF RESPIRAT

BIOPHYTIS ORGANISES A WEBCAST WITH KEY OPINION LEADERS (KOL) ON THE PHASE 2-3 COVA STUDY RESULTS OF SARCONEOS (BIO101) IN THE TREATMENT OF PNEUMONIA IN COVID-19 PATIENTS AT RISK OF RESPIRATORY FAILURE

Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of repiratory failure, Biophytis management is inviting all of Biophytis’ stakeholders to an online event with KOL.

Paris (France), Cambridge (Massachusetts, U.S.), November 30th, 2022, 23pm CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today invited all its shareholders to an online event where Key Opinion Leaders as well as Biophytis’ management will present an update of COVID-19 pandemic, the results of the phase 2-3 COVA study and discuss next regulatory steps for marketing authorization of Sarconeos (BIO101) in patients hospitalized with COVID-19 at risk of respiratory failure and death.

The presentation will be held in presence of :

• Dr Girish Balachandran Nair, MD – Associate Professor of Medicine in Respiratory and Critical Care, Beaumont Hospital, Royal Oak, MI, USA and Principal Investigator of the COVA study in the USA
• Professor Suzana Lobo, MD – Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto, São Paulo, Brazil and Investigator of the COVA study in Brazil

The webcast event will be held in English and followed by a Q&A session, on the 1st of December at 6 PM CET (12 AM ET).  You can register at : https://www.financelive.fr/biophytis/inscription/